Aventis Pharmaceuticals Inc.

Genzyme Corporation

Sungtaek Lim

Kwon Yon Musick

David Stefany

Hazel Joan Dyke

Stefan Peukert

Michael R Angelastro

Bradford Hirth

Shujaath Mehdi

Philip M Weintraub

Paul Robert Eastwood

Charles J Gardner

Timothy A Gillespy

John Ziqi Jiang

Elina Makino

Elsa Amandine Dechaux

Mary A Cromwell

Bin Cao

Keith John Harris

Neil Moorcroft

Uwe Schwahn

Robert H Barker, Jr

Sachin Maniar

Joacy C Aguiar

Ray Boffey

James Pribish

Yong-Mi Choi

Mark Munson

John Jiang

Paul R Eastwood

David W Stefany

Ray Argenta Discovery Ltd Boffey

Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).

UDP glycosyltransferase inhibitors and methods of use

The present invention is directed to a compound of Formula (I) wherein Cy, Cy, L, L, and Rare as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists

The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R, R, Rand Rare as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP)

Growing community of inventors

Flemington, NJ, United States of America

Sungtaek Lim